DOCSLIB.ORG

Gliclazide 80Mg Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gliclazide 80Mg Tablets Package leaflet: Information for the patient Gliclazide 80mg tablets Read all of this leaflet carefully before you • have an inherited condition where your red blood cells don’t start taking this medicine because it contains produce enough of the enzyme G6PD (glucose 6 phosphate important information for you. dehydrogenase) • Keep this leaflet. You may need to read it again. • suffer from particular hormone-induced disorders (functional disorders of the thyroid gland, of the pituitary gland or adrenal • If you have any further questions, ask your doctor cortex) or pharmacist. • are at risk of developing low blood sugar (hypoglycaemia) • This medicine has been prescribed for you only. - take meals irregularly or skip meals altogether, are fasting, Do not pass it on to others. It may harm them, malnourished, change your diet, increase your physical activity even if their signs of illness are the same as yours. and carbohydrate intake does not match this increase, drink • If you get any side effects, talk to your doctor or alcohol, especially in combination with skipped meals pharmacist. This includes any possible side effects • take other medicines or natural remedies at the same time not listed in this leaflet. See section 4. • take too high doses of gliclazide. You should observe the treatment plan prescribed by your What is in this leaflet doctor to achieve proper blood sugar levels. This means, apart 1 What Gliclazide tablets are and what from regular tablet intake, to observe the dietary regiment, have physical exercise and, where necessary, reduce weight. During they are used for gliclazide treatment, regular monitoring of your blood (and 2 What you need to know before you take possibly urine) sugar level and also your glycated haemoglobin Gliclazide tablets (HbA1c) is necessary. 3 How to take Gliclazide tablets Cases of acute porphyria have been described with some other sulfonylurea drugs, in patients who have porphyria (inherited 4 Possible side effects genetic disorders with accumulation in the body of porphyrins or 5 How to store Gliclazide tablets porphyrin precursors). 6 Contents of the pack and other Other medicines and Gliclazide tablets information Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including 1 What Gliclazide tablets are and what they are medicines obtained without a prescription. Especially: used for • other medicines used to treat high blood sugar (oral Gliclazide is one of a group of medicines called sulfonylureas antidiabetic, GLP-1 receptor inhibitors or insulin) that are used to lower the blood sugar level. • antibiotics (sulfonamides, clarithromycin) Gliclazide tablets are used to treat maturity onset diabetes in • medicines to treat high blood pressure such as beta blockers patients that is not controlled by diet alone. (e.g. propranolol, atenolol), ACE inhibitors (e.g. captopril), They are not for use in children or in patients with diabetes Angiotensin-II antagonists (e.g. losartan), nifedipine, diazoxide requiring insulin. • medicines used to treat infections such as co-trimoxazole, fluconazole, rifampicin, chloramphenicol, oral forms of 2 What you need to know before you take miconazole (see section 2), sulfonamides such as Gliclazide tablets sulfafurazole or tetracycline compounds (e.g. tetracycline) Do not take Gliclazide tablets and tell your doctor if • medicines used to prevent blood clotting (e.g. warfarin) you: • medicines used to treat depression such as monoamine oxidase • are allergic to gliclazide or any of the ingredients of this inhibitors (MAOIs e.g. moclobemide) medicine (listed in section 6), to other medicines of the same • medicines used to treat mental health problems such as lithium, group (sulfonylureas) or other related medicines (hypoglycaemic phenothiazine derivatives (e.g. prochlorperazine) sulfonamides). An allergic reaction may include a rash, itching, • corticosteroids (e.g. prednisolone), glucocorticoids and difficulty breathing or swelling of the face, lips, throat or tongue tetracosactrin used to reduce inflammation in the body • are breast feeding • phenylbutazone, azapropazone and other NSAIDs (non- • have severe liver or kidney disease steroidal anti-inflammatory drugs) • have porphyria (a hereditary disease affecting the liver or bone • diuretics (water tablets) such as bendroflumethiazide, marrow) hydrochlorothiazide, furosemide • have ever had a severe diabetic reaction (such as “acidosis” or • oral contraceptives (the “pill”) diabetic coma). • salicylates (e.g. aspirin used for muscular or skeletal disorders) • have Type I diabetes • sulfinpyrazone (used for gout) • are diabetic and need an operation, suffered a severe trauma • aminoglutethimide (used to treat breast or prostate cancer) or infection • hormones such as testosterone, octreotide or thyroid hormones • take miconazole (for fungal infections). (e.g. thyroxine) • cimetidine (used to treat stomach ulcers) Warnings and precautions • clofibrate (used to treat high cholesterol in the blood) Talk to your doctor or pharmacist before taking Gliclazide tablets • disopyramide (for irregular heartbeats) if you: • laxatives • have liver or kidney problems • other medicines used to treat high blood sugar Continued top of next column • medicines containing alcohol Continued over page 148x210 Leaflet Reel Fed Profile (BST) Gliclazide BP, Tablets, 80mg, Gliclazide 80mg Tablets PIL - UK 28s & 60s - UK JDE No.: 50999668 approved for print/date Item number: BBBB1095 Colours Non Printing Colours 1. Black 1. Profile Originator: NM Dimensions: 148x210 Dimensions: 148x210 (Reel Fed) 2. 2. Origination Date: 07/04/2021 Min Body Text Size: 7.5pts Revision Date: Supplier: Accord Barnstaple 3. 3. Component: Leaflet for Blisters Revised By: 4. 5. Pharmacode: Proof Round 1450 Technical Date sent: N/A 6. 01 Approval Date received: Date Sent: 29-03-21 [email protected] Technologist: RH Cartons and label leaflets only (labels only when specified) Technically Approved * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 7 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 12.02.2020 • chlorpromazine to treat disorders of the central nervous system • Angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, • medicines to treat asthma or used during labour (intravenous tongue or throat that may result in breathing difficulty). salbutamol, ritodrine and terbutaline) • Signs of severe hypersensitivity reactions (DRESS) (initially as flu-like • danazol to treat breast disorders, heavy menstrual bleeding and symptoms and a rash on the face then an extended rash with a high endometriosis temperature). • St John’s Wort (Hypericum perforatum) preparations • A rash progressing to widespread blistering or peeling of the skin. Blood glucose disturbance (low blood sugar and high blood sugar) can occur when a medicine belonging to a class of antibiotics called • Symptoms of low blood sugar level (hypoglycaemia) (sweating, fluoroquinolones is taken at the same time as Gliclazide tablets, clammy skin, trembling, weakness, double vision, palpitations, especially in elderly patients. confusion, headache, hunger, feeling or being sick, sleep disorders, feeling agitated, unable to concentrate, drowsiness, loss of Gliclazide tablets with alcohol consciousness, slowed reactions, depression, trouble seeing or Patients should not consume alcohol in combination with Gliclazide speaking, paralysis, numbness, dizziness, loss of self-control, sensing or tablets. seeing things that are not there, difficulty breathing, slowed or faster heartbeat, chest pains (angina)). Pregnancy and breast-feeding Gliclazide tablets are not recommended for use during pregnancy. If you • Hepatitis or liver failure causing fatigue, weakness, loss of appetite, are pregnant, think you may be pregnant or are planning to have a baby, weight loss, fever, changes in liver enzymes (seen in tests), jaundice ask your doctor for advice before taking this medicine. (yellowing of the skin or whites of the eyes). You must not take Gliclazide tablets while you are breastfeeding. Tell your doctor if you notice any of the following side effects or notice any other effects not listed: Driving and using machines Provided your blood glucose levels are satisfactorily controlled on Gastrointestinal - feeling or being sick, abdominal pain or discomfort, Gliclazide tablets, your ability to drive or use machines should not be indigestion, diarrhoea, constipation. affected. However, if your blood glucose levels become too low, this Skin - skin rashes or pale skin, redness, itching and hives. could adversely affect your concentration, and therefore your ability to Blood - gliclazide may affect the cells in your blood, which can cause perform these tasks. anaemia or mean that you are more likely to catch infections or have a Ask your doctor whether you can drive a car if you: fever or sore throat, or develop bruising or bleeding. • have frequent episodes of low blood sugar (hypoglycaemia), Eye disorders - Your vision may be affected for a short time, especially at • have few or no warning signals of low blood sugar. the start of treatment. This effect is due to changes in blood sugar levels. Other - general feeling of being unwell, reduction in blood sodium 3 How to take Gliclazide tablets Always take this medicine exactly as your doctor or pharmacist has told (hyponatraemia). you. Check with your doctor
Load more

Recommended publications
  • Environmental Risk Management for Pharmaceutical Compounds
    RISK MANAGEMENT AND REGULATORY ASPECTS Environmental risk managementfor pharmaceutical compounds Nick Voulvoulis1 imperial College London Introduction Pharmaceuticals are a highly variable group of organic compounds with the potential to cause harm to aquatic ecosystems and human health. Thousands of tones of pharmacologically active substances are used annually but surprisingly little is known about their ultimate fate in the environment (Jones et al., 2001). The data collected to date, rarely provide information on the processes that determine their environmental fate and although they receive considerable pharmacological and clinical testing during development, knowledge of their ecotoxicity is poor. One major concern is that antibiotics found in sewage effluent may cause increased resistance amongst natural bacterial populations (Willis, 2000). The debate over risks associated with chemicals in the environment represents more than just another disagreement in the scientific community. It has opened the door to a new way of thinking about the onset of uninherited diseases, the nature of scientific investigation, and the role of scientific knowledge in the policymaking process. Forexample, research evidence on endocrine disruption collected over the last few years has changed dramatically the way we think about chemical risks. In part, this change has also been attributed to the precautionary principle, as a new approach to environmental policy forged in Europe. The term "precautionary approach" declares an obligation to control the dangerous substances even before a definitive causal link had been established between the chemicals and health or environmental effects, and represents a radical departure from traditional approaches to risk assessment and particularly risk management, which includes an integration of the assessment, communication and mitigation of risks.
    [Show full text]
  • 19Th Expert Committee on the Selection and Use of Essential Medicines
    Expert Peer Review 2 19th Expert Committee on The Selection and Use of Essential Medicines April 8‐12 2013 Expert peer review on glibenclamide vs gliclazide, glipizide and glimepiride in the elderly. 1. Assessment of efficacy a. Have all relevant studies on efficacy been included No 1. Bollen S et al .Comparative efficacy and safety of oral diabetic medications for patients with Type 2 Diabetes AHRQ Publication No07 ‐ EHC010‐ EF July 2007 Comparative effectiveness review No. 8 A metanalysis done by these reviewers showed that there was no difference in the efficacy of Glibenclamide in reducing HbA1c as compared to Gliclazide, Glipizide and Glimepiride 2. Harrower AD. Comparison of diabetic control in type 2 (non‐insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin. 1985;9(10):676‐80. In this unblinded trial, Gliclazide was significantly better in reducing HbA1c than Glipizide 3. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, Novials A, Rottiers R, Rutten GE, Shaw KM.GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004 Aug;34(8):535‐42. In this study once daily sustained release Gliclazide was shown to be as effective as Glimepiride in reducing HbA1c. b. Summarize the data on efficacy, in comparison to what is listed in EML where applicable (limit to 2 to 3 sentences) On metanalysis, Glibenclamide was not superior to Gliclazide, Glipizide and Glimepiride in reducing HbA1c. Gliclazide was significantly better in reducing HbA1c than Glipizide in 1 unblinded trial.
    [Show full text]
  • Marketing Authorisations Granted in December 2020
    Marketing authorisations granted in December 2020 PL Number Grant Date MA Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status Territory PL 14251/0100 01/12/2020 MANX HEALTHCARE LIMITED COLCHICINE 500 MICROGRAMS TABLETS COLCHICINE 0.500 MILLIGRAMS POM UK PL 34424/0050 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 25MG FILM-COATED TABLETS SPIRONOLACTONE 25 MILLIGRAMS POM UK PL 34424/0051 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 50MG FILM-COATED TABLETS SPIRONOLACTONE 50 MILLIGRAMS POM UK PL 34424/0052 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 100MG FILM-COATED TABLETS SPIRONOLACTONE 100 MILLIGRAMS POM UK PL 36282/0021 03/12/2020 RIA GENERICS LIMITED COLCHICINE 500 MICROGRAM TABLETS COLCHICINE 500 MICROGRAMS POM UK PL 39352/0439 03/12/2020 KOSEI PHARMA UK LIMITED FROVATRIPTAN 2.5 MG FILM-COATED TABLETS FROVATRIPTAN SUCCINATE MONOHYDRATE 2.5 MILLIGRAMS POM UK PL 31750/0174 04/12/2020 SUN PHARMACEUTICAL INDUSTRIES EUROPE BV CETRORELIX SUN 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE CETRORELIX ACETATE 0.25 MILLIGRAMS PER MILLILITRE POM UK PL 34424/0054 04/12/2020 KEY PHARMACEUTICALS LIMITED ALIMEMAZINE TARTRATE 10MG FILM COATED TABLETS ALIMEMAZINE TARTRATE 10.00 MILLIGRAMS POM UK PL 17780/0858 07/12/2020 ZENTIVA PHARMA UK LIMITED FINGOLIMOD ZENTIVA 0.5 MG HARD CAPSULES FINGOLIMOD HYDROCHLORIDE 0.56 MILLIGRAMS POM UK PL 01502/0113 08/12/2020 HAMELN PHARMA LTD AMIODARONE HYDROCHLORIDE 20 MG/ML SOLUTION FOR INFUSION AMIODARONE HYDROCHLORIDE 20 MILLIGRAMS POM UK PL 16786/0006 08/12/2020
    [Show full text]
  • Gliclazide MR Versus Glyburide for Management of Type 2 Diabetes: a Review of the Clinical Effectiveness and Safety
    TITLE: Gliclazide MR versus Glyburide for Management of Type 2 Diabetes: A Review of the Clinical Effectiveness and Safety DATE: 03 March 2009 CONTEXT AND POLICY ISSUES: About 5% of the Canadian population has diabetes mellitus, an endocrine disorder that is characterized by hyperglycemia (high blood glucose) that results from defective insulin secretion, defective insulin action, or a combination of the two.1 Diabetes mellitus is further classified as type 1, type 2, or gestational diabetes. Type 2 diabetes accounts for the majority of diabetes cases and can be managed through lifestyle modification (e.g. diet and exercise), oral medications that lower blood glucose, and insulin.1 Canadian Diabetes Association Guidelines for the management of type 2 diabetes recommend the use of sulfonylureas (medications which increase the secretion of insulin from the pancreas to lower blood glucose) in individuals whose blood glucose is not adequately controlled with diet, exercise, and metformin, an oral medication that potentiates that the effects of insulin.1 There are a number of sulfonylureas available on the market in Canada, two of which are gliclazide and glyburide (also referred to as glibenclamide).1 Glyburide is administered orally at dosages of 5 mg to 20 mg daily.2 Depending on the dose, glyburide is administered once or twice daily.2 Gliclazide is available in a modified release (MR) preparation that allows the drug to be orally administered once daily at dosages of 30 mg to 120 mg.3 Gliclazide MR has a hydrophilic polymer matrix that
    [Show full text]
  • Prescribing Information 1. Generic Name Paracetamol and Mefenamic
    Not to be sold by retail without the prescription of a Registered Medical Practitioner Prescribing Information 1. Generic Name Paracetamol and Mefenamic Acid Suspension (Brand Name: MEFTAGESIC ®- P Suspension) Paracetamol: Box Warning About Its Liver Toxicity Taking more than daily dose may cause serious liver damage or allergic reactions (e.g., swelling of the face, mouth and throat, difficulty in breathing, itching or rash). The risk of liver injury primarily occurs when patient take multiple products containing paracetamol/acetaminophen at one time and exceed the current maximum dose of 4,000 mg within a 24-hour period. 2. Qualitative and Quantitative Composition Each 5 ml contains: Paracetamol IP ……………………………………..… 125 mg. Mefenamic Acid IP ………………………………..… 50 mg. Flavored Syrup Base…………………………………... q.s. Colour: Sunset Yellow FCF. 3. Dosage Form and Strength Dosage Form: Oral liquid (suspension). Dosage Strength: Paracetamol 125 mg with Mefenamic Acid 50 mg per 5 ml. 4. Clinical Particulars 4.1 Therapeutic Indication MEFTAGESIC-P Suspension is indicated in the treatment of fever. This medicine is also useful for the treatment of mild to moderate pain of varied etiologies. 4.2 Posology and Method of Administration For oral administration in children above 6 months of age. Recommended dosage of individual ingredients based on body weight. Paracetamol: 50-75 mg/kg daily in divided doses, or 10 to 15 mg/kg/dose every 4 to 6 hourly. Mefenamic Acid: 25 mg/kg daily in divided doses, or 4 to 6.5 mg/kg/dose every 8 hours. Recommended dosage of MEFTAGESIC-P Suspension based on age group. 6 months to 1 year: 5 ml to be administered three times daily.
    [Show full text]
  • HPMC AS HG Amorphous Solid Dispersions: Dissolution Enhancement Using Hot Melt Extrusion Technology
    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2019 Mefenamic Acid – HPMC AS HG Amorphous Solid Dispersions: Dissolution Enhancement Using Hot Melt Extrusion Technology Ashay Shukla University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Statistics and Probability Commons Recommended Citation Shukla, Ashay, "Mefenamic Acid – HPMC AS HG Amorphous Solid Dispersions: Dissolution Enhancement Using Hot Melt Extrusion Technology" (2019). Electronic Theses and Dissertations. 1690. https://egrove.olemiss.edu/etd/1690 This Thesis is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. Mefenamic acid – HPMC AS HG amorphous solid dispersions: dissolution enhancement using Hot Melt Extrusion Technology A Thesis Presented for the Master of Science Degree The University of Mississippi ASHAY SHUKLA May 2019 Copyright © 2019 by Ashay Shukla All rights reserve ABSTRACT Mefenamic acid, a BCS class II drug, displays high permeability and low solubility, thereby exhibiting a poor dissolution profile. Hence to improve the solubility and dissolution rate of Mefenamic acid, Hot Melt Extrusion (HME) technique was employed. The amorphous solid dispersion matrix exhibited enhanced dissolution with desired release characteristics. Hydroxypropylmethylcellulose acetate succinate (AquaSolve™ HPMC-AS HG) was used as a carrier with the poloxamer (Kolliphor P407). The drug load was varied from 20% to 40% within the blend. Drug and polymers were blended using a twin shell V-blender for 10 minutes and extruded using an 11mm twin-screw co-rotating extruder (ThermoFisher Scientific, Waltham, MA, USA).
    [Show full text]
  • Starlix, INN-Nateglinide
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Starlix. This scientific discussion has been updated until 1 February 2004. For information on changes after this date please refer to module 8B. 1. Introduction Starlix (nateglininde) is indicated for combination therapy with metformin of type 2 diabetes patients inadequately controlled despite a maximally tolerated dose of metformin alone. The daily dose is 60- 180 mg daily. Nateglinide is an aminoacid derivative of phenylalanine. Nateglinide is not structurally related to sulphonylureas. However, the mechanism of action is similar: nateglinide is an insulin secretagogue, decreasing blood glucose levels. 2. Chemical, pharmaceutical and biological aspects Composition Starlix film-coated tablets are available in 60 mg, 120 mg and 180 mg strengths containing nateglinide INN as the active substance. In addition to the active substance, the film-coated tablets contain standard excipients that are commonly used in solid oral dosage forms, chiefly lactose and microcrystalline cellulose. The remaining core ingredients are croscarmellose sodium, povidone and magnesium stearate. The primary packaging consists of a thermoformed blister using rigid plastic films, PVC/PE/PVDC backed with a heat-sealable lacquered aluminium foil: thermolacquer/aluminium/external protective coating. Active substance Nateglinide is N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine, a chiral molecule which has no structural resemblance to other antidiabetic drugs. It is manufactured by a third party and information was supplied in the form of an open and closed DMF. The process validation and investigation of potential critical parameters was satisfactory to assure a consistent good quality and purity of the active substance.
    [Show full text]
  • Annual Report 2014-15 Dr
    ANNUAL REPORT 2014-15 DR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT ANNUAL LIMITED | LABORATORIES REDDY’S DR. 2014-15 Good Health Can’t Good Health Can’t Wait. Can’t Good Health Wait. Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034, India www.drreddys.com In this report Our Brand 1 Chairman’s Letter 2 Living the Good Health Belief 4 Our Businesses 6 Key Performance Indicators 8 Case Study 1: 10 Diseases don’t care who pays for the medicine. Case Study 2: 12 Little children can’t wait to smile. Case Study 3: 14 Medication can’t be taken lightly. Case Study 4: 16 Good fortunes don’t last forever. Case Study 5: 18 Good health takes everyone along. Board of Directors 20 Management Council 24 Business Responsibility Report 26 The future belongs, Management Discussion & Analysis 40 not to those who Corporate Governance Report 54 merely seek Additional Shareholders’ Information 71 opportunity, but to Five Years at a Glance and Ratio Analysis 82 those who create Board's Report 84 it. Let us have the Standalone Financial Statements 109 courage to do Consolidated Financial Statements 163 things differently. Extract of Audited IFRS Consolidated Financial Statements 221 -Dr. K Anji Reddy Glossary 224 Notice of the Annual General Meeting 225 Our Brand We are in the business of good health and are driven by an imperative to accelerate access to affordable and innovative medicines to people who need them. We don’t see medicines just as molecules but as a medium to help people get back to good health.
    [Show full text]
  • ACCEPTABLE COMBINATIONS of DIABETES MEDICATIONS (Updated 01/27/2021)
    ACCEPTABLE COMBINATIONS OF DIABETES MEDICATIONS (Updated 01/27/2021) The chart on the following page outlines acceptable combinations of medications for treatment of diabetes. Please note: • Initial certification of all applicants with diabetes mellitus (DM) requires FAA decision; • Use no more than one medication from each group (A-F); • Fixed-dose combination medications - count each component as an individual medication. (e.g., Avandamet [rosiglitazone + metformin] is considered 2-drug components); • Up to 3 medications total are considered acceptable for routine treatment according to generally accepted standards of care for diabetes (American Diabetes Association, American Association of Clinical Endocrinologists); • For applicants receiving complex care (e.g., 4-drug therapy), refer the case to AMCD; • For applicants on AASI for diabetes mellitus, follow the AASI; • Consult with FAA for any medications not on listed on the chart; • Observation times: When initiating NEW diabetes therapy using monotherapy or combination medications: Adding Medication Observation Time Group A ONLY 14 days Group B-D 30 days Group E1 60 days When ADDING a new medication to an ESTABLISHED TREATMENT regimen: Current Medication Adding Medication Observation Time on Group A-D + new Group A-D 14 days on Group E1 + new Group A-D 30 days on Group A-D + new Group E1 60 days Note: If transitioning between injectable GLP-1 RA and oral GLP-1 RA formulation = 72 hours When initiating NEW or ADDING therapy for any regimen (new or established therapy): Adding Medication Observation Time Group F (SGLT2 inhibitors) 90 days Group E2 (insulin): • For agency ATCSs (non-CGM or CGM protocol) 90 days • For Pilots / Part 67 applicants, class 3 non-CGM 90 days protocol only: 180 days • For Pilots / Part 67 applicants, any class CGM protocol: ACCEPTABLE COMBINATIONS OF DIABETES MEDICATIONS (Updated 01/27/2021) Biguanides A -metformin (e.g.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Effects of Metformin Plus Gliclazide Versus Metformin Plus Glimepiride on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus
    Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus Memy Hegazy Hassan1,2* and Gamil Mohamed Abd-Allah3 1Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, El-Madinah El-Munaworah, KSA 2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azahr University, Cairo, Egypt 3Department of Biochemistry, Faculty of Pharmacy, Al-Azahr University, Cairo, Egypt Abstract: High blood glucose level, lipid profile disturbances and plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes. This study was conducted to evaluate and compare effects of glimepiride/metformin combination versus gliclazide/metformin combination on cardiovascular risk factors in type-2 diabetes mellitus (T2DM) patients. One hundred and eighty T2DM patients were randomly allocated for treatment with placebo (control), metformin (500mg twice daily), glimepiride (3mg once daily), gliclazide (80mg once daily), metformin plus glimepiride or metformin plus gliclazide for 3 months. We evaluated plasma levels of glucose (PG), glycated hemoglobin (HbA1C), Hcy, vitamin B12, folic acid and lipid profile before treatment and 3 months post treatment. Compared to metformin treated patients, glimepiride plus metformin induced significant reductions in: fasting plasma glucose, postprandial PG level, HbA1C % and Hcy level. Conversely, plasma folic acid and vitamin B12 were significantly increased. The levels of total cholesterol and triglyceride were significantly decreased; low-density lipoprotein was markedly decreased, whereas high-density lipoprotein was significantly increased and hence risk ratio was significantly decreased. Similar results but with lower values were obtained using combination of metformin plus gliclazide on glycemic control only.
    [Show full text]
  • Enhancement of in Vivo Hypoglycemic Effect of Gliclazide by Developing
    Patel et al. Future Journal of Pharmaceutical Sciences (2020) 6:17 Future Journal of https://doi.org/10.1186/s43094-020-00034-0 Pharmaceutical Sciences RESEARCH Open Access Enhancement of in vivo hypoglycemic effect of gliclazide by developing self- microemulsifying pellet dosage form Hetal Patel1* , Niharika Pandey1, Bhoomi Patel1, Ketan Ranch1, Kunjan Bodiwala2 and Bhavin Vyas1 Abstract Background: The present research was aimed to develop a self-microemulsifying drug delivery system (SMEDDS) pellet to increase the dissolution rate and in vivo hypoglycemic effect of gliclazide. Gliclazide belongs to BCS class 2 and it exhibits dissolution rate-limited absorption. Thus, dissolution enhancement of gliclazide from its dosage form is a prime requirement to achieve a better therapeutic effect. The solubility of gliclazide was estimated in oils, surfactants, and co-surfactants. A most effective self-emulsification region was identified using pseudoternary phase diagrams. The optimized liquid SMEDDS gliclazide formulation was converted to SMEDDS pellets using the extrusion-spheronization technique. The in vitro release and hypoglycemic effect of SMEDDS was compared with the marketed product. Results: The optimized liquid gliclazide SMEDDS formulations contained mixtures of Tween 80 and PEG 400 and Capmul MCM C8. The gliclazide SMEDDS in liquid preparation quickly formed a fine oil-in-water microemulsion having a globule size of 31.50 nm. In vitro release of gliclazide from SMEDDS pellets was 100.9% within 20 min. SMEDDS pellets exhibited a significant reduction in plasma glucose levels in albino mice compared to the marketed product. Conclusion: The results indicated that SMEDDS pellets could be effectively used to improve the oral delivery of gliclazide.
    [Show full text]